Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.62 +3.70 (+7.55%)
Streaming Delayed Price Updated: 3:35 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
35 36 Next >
News headline image
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
News headline image
CRSP Stock Earnings: CRISPR Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
CRSP stock results show that CRISPR Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments. 
Via InvestorPlace
News headline image
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar ↗
The gene editing stocks are worth tuning into as some investors out there discount their innovative, albeit early-stage pipelines. 
Via InvestorPlace
News headline image
3 Growth Stocks You’ll Kick Yourself for Not Buying Today ↗
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns. 
Via InvestorPlace
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today ↗
 
Via Benzinga
News headline image
Is It Too Late to Buy CRISPR Therapeutics Stock? ↗
The biotech has been making a lot of noise since late last year. 
Via The Motley Fool
News headline image
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond ↗
It pays to develop novel medicines for life-threatening illnesses. 
Via The Motley Fool
News headline image
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire ↗
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
News headline image
Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge ↗
A slip in the market could give investors a rare opportunity to get some top biotech stocks to buy at a considerable discount. 
Via InvestorPlace
News headline image
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗
Good news could be just around the corner for two drugmakers not named Novo Nordisk. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? ↗
Vertex is broadening its portfolio. 
Via The Motley Fool
News headline image
3 Magnificent Stocks That Could Double or More by 2030 ↗
There's no guarantee these stocks will double by 2030, but their growth prospects look great. 
Via The Motley Fool
News headline image
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024 ↗
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024. 
Via InvestorPlace
News headline image
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics ↗
These rising drugmakers have serious arguments in their favor. 
Via The Motley Fool
News headline image
Bull Market and Beyond: 3 Stocks Just Waiting to Soar ↗
These stocks, a bargain today, are players to hold on to for the long term. 
Via The Motley Fool
News headline image
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics ↗
These companies are in the early days of their growth stories. 
Via The Motley Fool
News headline image
3 Unstoppable Stocks to Buy Hand Over Fist in April ↗
These stocks have exceptionally bright prospects. 
Via The Motley Fool
News headline image
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why ↗
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition ↗
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine. 
Via InvestorPlace
News headline image
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000 ↗
Each of these three companies are entering a new era of growth. 
Via The Motley Fool
News headline image
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move ↗
The price could be right for these three biopharma stocks. 
Via The Motley Fool
News headline image
3 Stocks That Could Be the Next Big Thing in Gene Editing ↗
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
News headline image
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
News headline image
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024 ↗
These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge. 
Via InvestorPlace
News headline image
7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
News headline image
Cathie Wood's Ark Invest Keeps Dumping Coinbase Shares Amid Bitcoin, Crypto Buzz ↗
On Tuesday, Cathie Wood-led Ark Invest made a significant move by offloading a substantial number of shares in Coinbase Global Inc (NASDAQ:COIN), despite Bitcoin (CRYPTO: BTC) reaching new 
Via Benzinga
News headline image
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗
Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23. 
Via Talk Markets
News headline image
The Top 3 Biotech Stocks to Buy in March 2024 ↗
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors. 
Via InvestorPlace
News headline image
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.